---
canonical_name: 7,8-Dihydroxyflavone
alternate_names: Tropoflavin, 7,8-DHF
canonical_topic: 7,8-Dihydroxyflavone for Health & Longevity
short_topic_lc: 78_dihydroxyflavone
creation_date: 2026-0724-0007
creator_ai_fullname: Opus 4.8
---

# 7,8-Dihydroxyflavone for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 07/24/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8

**Also known as:** Tropoflavin, 7,8-DHF

  
## Motivation

<!-- This motivation section was written last, after the rest of the document was completed, so that it accurately reflects the full scope of the topic. -->

7,8-Dihydroxyflavone (also called tropoflavin) is a small plant-derived molecule found in trees such as *Godmania aesculifolia* and in the tridax daisy. It draws attention because it can imitate a natural brain protein that helps neurons grow, survive, and connect. The body's own version of that protein is hard to use as a medicine because it breaks down quickly and cannot reach the brain from outside. By switching on the same receptor the protein uses, 7,8-Dihydroxyflavone can turn on those growth signals with a compound that is swallowed and enters the brain.

First described as a receptor activator in 2010, it has since been tested in more than one hundred and eighty animal experiments spanning memory loss, mood, and body-weight control. This unusually large body of laboratory work, plus its sale as an inexpensive over-the-counter powder, has made it popular among people trying to protect brain health as they age. Human evidence, however, remains almost entirely absent.

This review examines what is known about 7,8-Dihydroxyflavone through the lens of long-term health and brain aging: its proposed benefits, its possible harms, how it is used, and the gap between encouraging animal findings and the thin evidence in people.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  
## Recommended Reading

This section highlights independent, high-level overviews of 7,8-Dihydroxyflavone from a priority health-and-longevity source and from in-depth scientific reviews that discuss the compound by name.

<!-- A real-time web search was performed across general search engines and the platforms of the priority experts (foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com, lifeextension.com) for content discussing 7,8-Dihydroxyflavone by name or via its primary mechanism. Relevant, high-level material was found from Rhonda Patrick (FoundMyFitness) and from several narrative scientific reviews. No dedicated content was found from Peter Attia, Andrew Huberman, Chris Kresser, or Life Extension Magazine. -->

* [BDNF mimetic 7,8-dihydroxyflavone protects neurons against cell death](https://www.foundmyfitness.com/stories/etloxu) - Rhonda Patrick

  Rhonda Patrick's FoundMyFitness summary distills the foundational 2010 discovery that 7,8-Dihydroxyflavone mimics brain-derived neurotrophic factor (BDNF, a protein that drives the growth, survival, and connection of neurons) by activating its receptor, tropomyosin receptor kinase B (TrkB, the docking site BDNF normally switches on). It is an accessible entry point that explains why a small, orally available BDNF mimic is of interest for protecting the aging brain.

* [7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders](https://pubmed.ncbi.nlm.nih.gov/26740873/) - Liu et al., 2016

  Written by members of the laboratory that discovered the compound, this narrative review lays out its receptor binding, structure-activity relationship, absorption and breakdown, and the range of animal disease models in which it has shown promise. It is the clearest single primer on the mechanism, though readers should note the authors' close involvement in developing the molecule.

* [Treatment with the flavonoid 7,8-Dihydroxyflavone: a promising strategy for a constellation of body and brain disorders](https://pubmed.ncbi.nlm.nih.gov/32914634/) - Emili et al., 2022

  This is the most exhaustive independent survey available, cataloguing more than 180 preclinical studies across brain and body conditions. Its value lies in giving the reader tools to weigh the animal evidence critically while making plain that the field has not yet moved "from the bench to the bedside."

* [7,8-Dihydroxyflavone and Neuropsychiatric Disorders: A Translational Perspective from the Mechanism to Drug Development](https://pubmed.ncbi.nlm.nih.gov/34525922/) - Yang & Zhu, 2022

  This review focuses on depression, neurodegeneration, and memory, and usefully highlights mechanisms beyond the TrkB receptor — antioxidant activity, interaction with estrogen receptors, and gut-flora effects — as well as the chemical modifications being explored to overcome the compound's poor drug-like properties.

* [7,8-Dihydroxyflavone: A Brain Health Supplement That May Support Neuroplasticity](https://nootropicsdepot.com/articles/7-8-dihydroxyflavone-a-brain-health-supplement-that-may-support-neuroplasticity/) - Nootropics Depot

  A consumer-facing explainer that describes the flavone's plant origins, its proposed brain effects, and practical points on stability and handling. It is useful for understanding how the compound is marketed and used, but it is published by a vendor that sells the product and should be read with that commercial interest in mind.

No dedicated, high-level content discussing 7,8-Dihydroxyflavone could be found from Peter Attia, Andrew Huberman, Chris Kresser, or Life Extension Magazine; the priority slots were therefore filled with the FoundMyFitness item and the most substantial independent scientific reviews.

  
## Grokipedia

<!-- grokipedia.com was searched directly using the browser tool. A dedicated article exists under the compound's synonym "Tropoflavin". -->

[Tropoflavin](https://grokipedia.com/page/Tropoflavin)

Grokipedia hosts a dedicated article under the synonym "Tropoflavin," covering the flavone's chemistry, its role as a receptor activator, and the preclinical research landscape. It is a useful orientation to the compound's identity and naming, including how the parent molecule relates to synthetic derivatives.

  
## Examine

<!-- examine.com was searched directly using the browser tool. A dedicated supplement page exists for the intervention. -->

[7,8-Dihydroxyflavone](https://examine.com/supplements/7-8-dihydroxyflavone/)

Examine maintains a dedicated, reference-backed page summarizing the flavone's mechanism, the animal evidence base, and the important caveat that no human studies exist to anchor dosing. It is a strong neutral counterweight to vendor marketing.

  
## ConsumerLab

<!-- consumerlab.com was searched directly using the browser tool. No dedicated product review, test report, or article on 7,8-Dihydroxyflavone was found; the search returned only unrelated supplement content. -->

No dedicated ConsumerLab article, product review, or independent test report for 7,8-Dihydroxyflavone was found. ConsumerLab does not currently cover this compound, which is sold as a niche research-grade nootropic rather than a mainstream supplement.

  
## Systematic Reviews

<!-- A real-time PubMed search was performed for "(7,8-dihydroxyflavone OR 7,8-DHF) AND (systematic review OR meta-analysis)" and for "dihydroxyflavone[Title] AND (systematic review OR meta-analysis)". No qualifying systematic reviews or meta-analyses were returned; the available secondary literature consists entirely of narrative reviews. -->

No systematic reviews or meta-analyses for 7,8-Dihydroxyflavone were found on PubMed as of July 24, 2026.

  
## Mechanism of Action

7,8-Dihydroxyflavone is a flavone — a plant pigment molecule — that acts primarily as a selective agonist (activator) of tropomyosin receptor kinase B (TrkB), the receptor normally switched on by brain-derived neurotrophic factor (BDNF, the neuron growth-and-survival protein introduced above). By binding the outer part of TrkB, it causes two receptor molecules to pair up and trigger the same internal cascades as BDNF.

The main downstream pathways are:

* **PI3K/Akt** (phosphoinositide 3-kinase / protein kinase B — a pro-survival signaling relay): promotes neuron survival and suppresses programmed cell death.
* **MAPK/ERK** (mitogen-activated protein kinase / extracellular signal-regulated kinase — a growth-signal relay): drives synapse formation and plasticity.
* **PLCγ–CREB** (phospholipase C-gamma feeding into CREB, a gene-activating switch): turns on genes involved in learning and memory.

Beyond the receptor, 7,8-Dihydroxyflavone has TrkB-independent actions that may contribute to its effects: it is an antioxidant that can activate the Nrf2 pathway (a master switch for the cell's own antioxidant defenses), it interacts with estrogen receptors, and it weakly inhibits monoamine oxidase (MAO, an enzyme that breaks down mood-related neurotransmitters).

There is genuine scientific debate about how much of the compound's activity is truly TrkB-mediated. Some independent laboratories have struggled to reproduce direct, high-affinity TrkB binding and argue that antioxidant and off-target actions explain much of the observed benefit. A 2024 study added a further twist by showing the molecule is a potent direct inhibitor of pyridoxal phosphatase (PDXP, an enzyme that degrades the active form of vitamin B6) — an effect unrelated to TrkB that could account for some biological activity and some risks. Both the "TrkB agonist" and the "multi-target flavonoid" explanations are presented here as competing, still-unsettled accounts.

**Key pharmacological properties:** 7,8-Dihydroxyflavone is orally active and crosses the blood-brain barrier (the filter separating blood from brain tissue), but its drug-like properties are poor. Oral bioavailability is low (estimated at roughly 5% in rodents) and its half-life (the time for blood levels to fall by half) is short — on the order of a few hours — driving the need for frequent or high dosing. It is not target-selective in the strict sense, given the off-target actions above. Distribution favors brain, liver, and kidney. Metabolism is dominated by conjugation — methylation (partly via catechol-O-methyltransferase, COMT, an enzyme that attaches methyl groups to catechol-like structures), glucuronidation, and sulfation — which rapidly inactivates the two hydroxyl groups that the molecule needs for activity.

  
## Historical Context & Evolution

7,8-Dihydroxyflavone was not developed as a drug; it is a naturally occurring flavone identified in plants long before its receptor activity was known. Its modern story began in 2010, when a group led by Keqiang Ye at Emory University ran a cell-based screen of roughly 2,000 bioactive compounds looking for small molecules that could imitate BDNF. 7,8-Dihydroxyflavone emerged as the lead hit: it protected cultured rodent and human neurons from death and activated TrkB.

The reason it moved from botanical curiosity to health-optimization candidate is straightforward. BDNF is central to learning, memory, mood, and neuron survival, and its decline is linked to aging, depression, and neurodegeneration — yet BDNF itself is almost useless as a therapy because it degrades quickly and cannot cross the blood-brain barrier. A small, orally available molecule that reproduced BDNF's signaling promised to sidestep those problems, which is why it rapidly became one of the most-studied "BDNF mimetics."

Over the following fifteen years the compound was tested in an enormous range of animal models — Alzheimer's disease, Parkinson's disease, depression, stroke, Rett syndrome, obesity, and aging among them — with many reports of benefit. Alongside this, chemists developed derivatives and prodrugs (for example, the prodrug known as R13) intended to improve absorption and durability. It is worth noting that the discovering laboratory holds patents on TrkB-agonist compounds and has commercial ties to their development, a financial interest that colors the framing of much of the foundational literature.

The evolution of opinion here is unusual: rather than a benefit being "debunked," the central open question is whether an impressive preclinical record will translate to humans at all. Skeptical work questioning direct TrkB binding, and the 2024 discovery of an unrelated enzyme-inhibiting action, have complicated — but not overturned — the original account. The current standing is best described as promising and heavily replicated in animals, but clinically unproven, with the direction of the evidence still actively contested on both sides.

  
## Expected Benefits

The benefits below are drawn almost entirely from cell and animal studies; no human clinical trials of 7,8-Dihydroxyflavone have been completed. Evidence grades therefore reflect the strength and consistency of preclinical data, and every grade should be read against the complete absence of human outcome data. For readers pursuing longevity, the realistic near-term value is as an experimental neuroprotective candidate, not an established one.

<!-- A dedicated search of PubMed and expert/clinical sources was performed to cross-check the completeness of the benefit profile across cognitive, mood, metabolic, neurodegenerative, ocular, and musculoskeletal domains. -->

### Low 🟩

#### Cognitive Function & Memory Support

The most heavily replicated finding is that 7,8-Dihydroxyflavone improves learning and memory in rodents, especially in models of Alzheimer's disease and normal aging. Proposed mechanisms are TrkB-driven increases in synapse number and dendritic spine density plus reductions in amyloid and tau burden. The evidence basis is dozens of independent animal studies (transgenic Alzheimer's mice such as 5XFAD and APP/PS1, and aged mice), which is consistent but limited by species and by the absence of any human cognitive testing.

**Magnitude:** In transgenic Alzheimer's mice, oral dosing (~5 mg/kg/day) restored novel-object-recognition and water-maze performance toward normal (wild-type) levels and increased thin-spine density; no human cognitive effect size exists.

#### Neuroprotection After Acute Neuronal Injury

In models of stroke, traumatic brain injury, and toxin exposure, the compound reduces neuron death and improves functional recovery, largely through the pro-survival PI3K/Akt pathway. The evidence basis is multiple rodent injury studies with consistent direction, though findings in acute-injury models translate poorly to humans historically.

**Magnitude:** In rodent stroke and traumatic-brain-injury models, ~20 mg/kg reduced infarct or lesion volume by roughly 30–50% and improved functional scores out to about 4 weeks post-injury.

#### Antidepressant- and Anxiety-Reducing Effects

7,8-Dihydroxyflavone produces antidepressant- and anxiety-reducing effects in standard rodent behavioral tests, consistent with the established link between BDNF-TrkB signaling and mood. The evidence basis is numerous animal studies plus mechanistic overlap with how conventional antidepressants raise BDNF; the main limitation is that behavioral-despair tests are imperfect proxies for human depression.

**Magnitude:** In rodent depression models, the compound reduced immobility in forced-swim and tail-suspension tests to a degree broadly comparable to reference antidepressants such as imipramine.

### Speculative 🟨

#### Metabolic Health & Body-Weight Regulation ⚠️ Conflicted

Some rodent work reports that 7,8-Dihydroxyflavone limits diet-induced weight gain, improves glucose handling, and reduces fat-tissue inflammation and insulin resistance, plausibly via TrkB signaling in energy-regulating brain regions and in fat tissue. The evidence is conflicting: several metabolic benefits appear pronounced in female mice but weak or absent in males, and effects vary with the model, so the finding cannot be generalized. The basis is a modest set of animal and cell studies only.

#### Parkinson's-Related Dopaminergic Protection

In toxin-based models of Parkinson's disease, the compound protects dopamine-producing neurons and preserves movement, again through TrkB-linked survival signaling. The basis is mechanistic and a handful of rodent studies; no human or primate confirmation exists.

#### Retinal & Optic-Nerve Protection

Because TrkB is expressed in the retina, 7,8-Dihydroxyflavone has been tested in models of glaucoma, retinal ischemia, and optic-nerve injury, with mixed protection of retinal ganglion cells. Reports range from meaningful benefit to minimal effect, so the basis is regarded as preliminary animal evidence only.

#### Skeletal-Muscle & Exercise-Mimetic Support

BDNF-TrkB signaling helps maintain muscle mitochondrial quality, and 7,8-Dihydroxyflavone has been proposed as a partial "exercise mimetic" that could support muscle health and counter age-related muscle loss. The basis is mechanistic reasoning plus a small number of animal studies, several of which show sex-specific effects; there is no human muscle data.

#### Broader Healthy-Aging & Longevity Signaling

By engaging survival and antioxidant pathways (PI3K/Akt, Nrf2) implicated in cellular aging, the compound is hypothesized to support general healthy aging beyond the brain. This remains entirely speculative: it rests on mechanistic plausibility and scattered aging-model reports, with no lifespan or healthspan data in any mammal at supplement-relevant exposures.

  
## Benefit-Modifying Factors

* **Genetic variation in BDNF signaling:** People carrying the common BDNF Val66Met variant (a change that reduces activity-dependent BDNF release) may have different baseline TrkB signaling, which could plausibly alter how much a TrkB agonist adds — though this has never been tested in humans for this compound.
* **Catechol-O-methyltransferase (COMT) activity:** Because COMT helps methylate and inactivate the flavone, individuals with faster COMT activity might clear it more quickly and see reduced benefit at a given dose.
* **Baseline biomarker levels:** Lower baseline BDNF-linked function (as seen with aging, depression, or physical inactivity) is the state in which a BDNF mimic would theoretically offer the most, whereas already-optimized, highly active individuals may gain little.
* **Sex-based differences:** Several metabolic and muscle effects are stronger in female animals, likely reflecting the compound's interaction with estrogen receptors; benefits may therefore differ meaningfully between women and men.
* **Pre-existing health conditions:** Neurodegenerative or mood conditions define the models where benefit is largest; in metabolically or neurologically healthy adults the marginal benefit is expected to be smaller.
* **Age:** Older adults, in whom BDNF signaling and neuron resilience decline, are the group in which the mechanistic rationale is strongest — but they are also the least-studied and most vulnerable to unknown risks.

  
## Potential Risks & Side Effects

The overriding risk of 7,8-Dihydroxyflavone is that its safety in humans is essentially unstudied; the specific items below are drawn from animal data, mechanism, and isolated reports. Grades reflect how well each risk is documented, not how severe it would be in a person.

<!-- A dedicated search of PubMed, drug/supplement references, and mechanistic literature was performed to cross-check the completeness of the risk and side-effect profile, including musculoskeletal, oncologic, nutritional, addiction, and product-quality concerns. -->

### Low 🟥

#### Impaired Bone & Fracture Healing

A controlled mouse study found that TrkB activation by 7,8-Dihydroxyflavone impaired the healing of bone fractures, an effect attributed to disruption of the normal nerve-and-vascular signaling that supports callus formation. The mechanism is biologically plausible because TrkB signaling influences bone remodeling, and a separate 2025 study links the pathway to bone metabolism. The main limitation is that this is animal evidence; relevance to human bone health is unproven but concrete enough to flag.

**Magnitude:** In the mouse study, daily dosing significantly reduced healing-callus size and the mechanical strength of the repairing bone compared with untreated controls.

### Speculative 🟨

#### Unknown Long-Term Human Safety

No completed human trials have characterized the safety, tolerability, or long-term consequences of taking 7,8-Dihydroxyflavone, and all human dosing is extrapolated mathematically from rodents. The basis for concern is the simple absence of data rather than a specific observed harm; chronic activation of a growth-signaling receptor is inherently something that warrants human study before routine use.

#### Vitamin B6 Metabolism Disruption

A 2024 study showed the compound is a direct, potent inhibitor of pyridoxal phosphatase, an enzyme in vitamin B6 metabolism. Depending on dose, this could either raise active vitamin B6 or perturb its balance, with uncertain downstream effects on many B6-dependent processes. The basis is a single mechanistic study, so the clinical meaning is unknown but plausible enough to monitor.

#### Theoretical Tumor-Promotion Risk

TrkB signaling and its downstream survival pathways are over-active in several cancers, where they can promote tumor cell survival and spread. A sustained TrkB agonist could in theory support the growth of an existing TrkB-driven tumor. This is a mechanistic concern with no direct evidence for or against in the context of this supplement, and is included on the basis of pathway biology and isolated oncology reports.

#### Potentiation of Addictive Behaviors ⚠️ Conflicted

Findings on addiction-related behavior conflict: in one rat model 7,8-Dihydroxyflavone reduced alcohol consumption, while in another it enhanced cue-triggered alcohol reinstatement (relapse-like behavior). Because BDNF-TrkB signaling has opposing roles across brain regions, the net effect on human addiction risk is genuinely unclear. The basis is a small number of contradictory rodent studies.

#### Pro-oxidant and Off-Target Effects at High Doses

Although generally antioxidant, catechol-containing flavones can behave as pro-oxidants at high concentrations, and the compound's off-target actions (enzyme inhibition, estrogen-receptor interaction) grow more relevant as dose rises. The basis is cell-culture observations and general flavonoid pharmacology; the practical threshold in humans is unknown.

#### Product Impurity, Oxidation & Mislabeling

Sold as an unregulated research-grade powder, the material can vary in purity, may be under- or over-dosed, and oxidizes on exposure to air, light, and moisture (visibly darkening), which degrades potency and could generate unwanted breakdown products. The basis is general supplement-quality experience and the compound's known chemical instability rather than product-specific testing.

  
## Risk-Modifying Factors

* **Genetic variation:** Slow catechol-O-metabolism or variants affecting flavonoid conjugation could raise systemic exposure and thereby amplify off-target and dose-dependent risks; no pharmacogenetic data specific to this compound exist.
* **Baseline biomarker levels:** Low baseline vitamin B6 status could make any perturbation of B6 metabolism more consequential, and abnormal baseline liver enzymes could signal reduced capacity to clear the compound.
* **Sex-based differences:** Estrogen-receptor interaction means hormonal status and sex may modify both benefits and risks, including in women who are pregnant or postmenopausal.
* **Pre-existing health conditions:** A personal history of cancer (especially TrkB-driven tumors), recent fractures or orthopedic surgery, and liver or kidney impairment are the conditions most likely to shift the risk balance unfavorably.
* **Age:** Older adults face both the greatest theoretical benefit and the greatest vulnerability to fracture-healing and unknown chronic effects, so the risk calculus is most delicate at the upper end of the target range.

  
## Key Interactions & Contraindications

Because human interaction data are absent, the following are derived from mechanism and the compound's known off-target actions, and should be treated conservatively.

* **Antidepressants (SSRIs, or selective serotonin reuptake inhibitors, such as sertraline and fluoxetine; SNRIs, or serotonin-norepinephrine reuptake inhibitors, such as venlafaxine):** Additive effect on BDNF-TrkB signaling. Severity: caution. Consequence: unpredictable over-stimulation of mood pathways. Mitigating action: avoid combining without medical oversight; do not adjust prescribed antidepressants.
* **Monoamine oxidase (MAO) inhibitors (phenelzine, selegiline):** The flavone's weak MAO inhibition could be additive. Severity: caution. Consequence: theoretical excess monoamine signaling. Mitigating action: avoid concurrent use.
* **Vitamin B6 supplements (pyridoxine):** Interaction with vitamin B6 metabolism via pyridoxal phosphatase inhibition. Severity: monitor. Consequence: unpredictable shifts in active B6 levels. Mitigating action: avoid high-dose B6 stacking and check B6 status if combined.
* **Anticoagulants and antiplatelet drugs (warfarin, aspirin, clopidogrel):** Flavonoids can affect platelet function and drug-metabolizing enzymes. Severity: caution. Consequence: possible increased bleeding tendency. Mitigating action: separate use and monitor for bruising or bleeding.
* **Drugs with narrow safety margins metabolized by CYP enzymes (CYP1A2 and CYP3A4 substrates — the liver's main drug-processing enzymes, e.g., theophylline, certain statins):** Flavones can inhibit these enzymes. Severity: caution. Consequence: raised levels of the co-administered drug. Mitigating action: timing separation and prescriber awareness.
* **Other BDNF-raising supplements and nootropics (e.g., other flavonoids, lion's mane):** Additive growth-signaling effect. Severity: monitor. Consequence: compounded, poorly characterized stimulation. Mitigating action: introduce one agent at a time.
* **Cancer therapies:** Potential opposition to the goal of suppressing tumor-cell survival. Severity: absolute contraindication during active cancer treatment. Consequence: theoretical support of tumor survival. Mitigating action: avoid entirely.

**Populations who should avoid this intervention:** people who are pregnant or breastfeeding; children (outside research); anyone with active malignancy or a history of TrkB-driven cancer; people within the healing window of a recent fracture or orthopedic surgery (roughly the first 6–12 weeks); and anyone with significant liver or kidney impairment. Given the absence of human safety data, cautious avoidance is reasonable for anyone unwilling to accept substantial uncertainty.

  
## Risk Mitigation Strategies

* **Start low and use the minimum effective amount:** Because human dosing is unvalidated, beginning well below commonly cited amounts (for example, a fraction of a ~25 mg capsule) limits exposure to the pro-oxidant and off-target effects that scale with dose.
* **Avoid during bone healing:** Given the mouse fracture-healing signal, discontinue in the weeks around a fracture or orthopedic surgery to avoid impairing callus formation.
* **Screen out cancer risk:** Because TrkB signaling can support tumor survival, avoid use with any active or recent malignancy — this prevents theoretically feeding a TrkB-driven cancer.
* **Protect and monitor vitamin B6 status:** To offset possible disruption of B6 metabolism, avoid stacking high-dose B6 and check B6-related status periodically.
* **Buy only third-party-tested material and store it properly:** Purchasing products with a certificate of analysis (COA, an independent lab report of identity and purity) and storing the powder cold, dry, and away from light mitigates the impurity, under-dosing, and oxidation risks inherent to an unregulated product.
* **Use time-limited trials and reassess:** Employing short cycles rather than open-ended daily use limits cumulative exposure to unknown chronic effects and creates natural checkpoints to reassess tolerance.

  
## Therapeutic Protocol

No validated human therapeutic protocol exists, because the compound has not completed clinical testing; the following reflects how experimental users and supplement vendors approach it, presented without endorsement.

* **Typical amounts used:** Community and vendor practice commonly centers on roughly 25–100 mg once daily, figures extrapolated from rodent studies (often ~5 mg/kg) rather than established in people; the uncertainty in this translation is large.
* **Competing approaches:** The main alternatives are (a) plain 7,8-Dihydroxyflavone powder or capsules taken orally, (b) sublingual or liposomal preparations intended to bypass poor absorption, and (c) experimental prodrugs such as R13 designed for better durability. None is proven superior in humans; they are presented as parallel options, not a default.
* **Who popularized use:** Interest traces to Keqiang Ye's discovery work at Emory University and was amplified in the nootropic community by vendors such as Nootropics Depot; the discovering laboratory's patent and commercial interests should be kept in view.
* **Best time of day:** Morning dosing is generally chosen because BDNF-linked stimulation could theoretically interfere with sleep if taken late.
* **Half-life considerations:** With a short half-life of only a few hours, a single daily dose does not sustain exposure; this is the rationale some users give for splitting doses.
* **Single versus split dosing:** Both are used — a single morning dose for simplicity, or split (for example, morning and midday) to counter rapid clearance.
* **Take with dietary fat:** As a poorly water-soluble flavone, it is typically taken with a fat-containing meal to modestly improve absorption.
* **Genetic considerations:** Faster catechol-O-methyltransferase (COMT) activity may increase clearance, a factor some users cite for dosing at the higher end, though no pharmacogenetic guidance is validated.
* **Sex-based differences:** Because several effects are stronger in females and the compound engages estrogen receptors, response and appropriate dosing may differ between women and men.
* **Age-related considerations:** Older adults may have the strongest rationale but also the greatest vulnerability, arguing for especially conservative amounts at the upper end of the target range.
* **Baseline biomarkers:** Checking baseline liver enzymes and vitamin B6 status before starting is prudent given the metabolic and hepatic clearance route.
* **Pre-existing conditions:** Mood, neurodegenerative, or metabolic conditions may change both the rationale and the risk, and warrant medical involvement before any use.

  
## Discontinuation & Cycling

* **Lifelong versus short-term:** There is no evidence to support open-ended lifelong use; given the unknown chronic safety profile, time-limited experimental use is the more defensible framing.
* **Withdrawal effects:** No physical dependence or withdrawal syndrome has been described in animals or humans; the compound can be stopped without a known rebound.
* **Tapering:** Because no withdrawal is known, a formal taper is not required, though gradual reduction is harmless if preferred.
* **Cycling for sustained effect:** Some users cycle (for example, several days on with breaks, or weeks on and off) on the theory that continuous TrkB stimulation could desensitize the receptor; this rationale is plausible but unproven, and cycling also usefully limits cumulative exposure.
* **Reassessment at stops:** Each break is best used to reassess subjective benefit, tolerability, and any change in monitored biomarkers before deciding whether to resume.

  
## Sourcing and Quality

* **Regulatory reality:** 7,8-Dihydroxyflavone is sold as an unregulated research-grade powder or capsule, not as an approved drug or a well-established dietary ingredient, so quality assurance falls entirely on the buyer.
* **What to look for:** Prioritize products accompanied by a certificate of analysis (COA) confirming identity, potency, and screening for heavy metals and solvent residues from third-party laboratories.
* **Form and stability:** Capsules protect against handling losses, while bulk powder is cheaper but harder to dose accurately; either way the material is prone to oxidation and should be fresh, pale-to-yellow rather than darkened, and stored cold, dry, and dark.
* **Reputable sources:** Vendors such as Nootropics Depot and Pure Nootropics are commonly cited for publishing testing data, though listing them is not an endorsement and does not overcome the lack of human safety evidence.
* **Purity over marketing:** Choose suppliers whose claims rest on published analytical testing rather than on health benefits, since benefit claims for this compound outrun the human evidence.

  
## Practical Considerations

* **Time to effect:** Unknown in humans; users describe subjective mood or focus changes over days to a few weeks, but there is no validated timeline and expectation-driven effects cannot be excluded.
* **Common pitfalls:** The frequent mistakes are taking it without dietary fat (worsening already-poor absorption), using oxidized or darkened material, over-dosing on the assumption that "more is better," and combining it with several other actives at once so that any effect or side effect cannot be attributed.
* **Regulatory status:** It is not approved by the FDA for any use and does not have recognized dietary-ingredient status; it occupies a legal gray area, often sold labeled "for research," and quality is not government-guaranteed.
* **Cost and accessibility:** It is inexpensive and easy to obtain online, so cost is not a barrier; the real limiting factor is evidential, not financial.
* **Overall framing:** Practically, it is best understood as a self-directed experiment with an unusually deep animal literature and an unusually shallow human one.

  
## Interaction with Foundational Habits

* **Sleep:** Direction — potentially disruptive if mistimed. BDNF-TrkB activation is linked to arousal and plasticity, so stimulation late in the day could theoretically impair sleep onset; the practical step is to dose in the morning and observe individual response.
* **Nutrition:** Direction — potentiating and dependent on diet. As a fat-soluble flavone, absorption improves when taken with a fat-containing meal, and a flavonoid-rich diet may act synergistically; conversely, its effect on vitamin B6 metabolism argues against pairing it with high-dose B6 supplementation.
* **Exercise:** Direction — overlapping/potentiating. Exercise is the most robust natural way to raise BDNF, so the compound may either complement training or partly duplicate a benefit already obtainable through activity; there is no evidence it should be timed to specific workouts, and it is not a substitute for exercise.
* **Stress management:** Direction — indirect and supportive. Because BDNF-TrkB signaling underpins stress resilience and mood, the compound's antidepressant-like actions could complement stress-reduction practices, though this is inferred from animal mood models rather than human stress data.

  
## Monitoring Protocol & Defining Success

Because this is an unproven, self-directed intervention, monitoring is precautionary — aimed at detecting harm and gauging subjective value rather than tracking an established therapeutic target. Baseline testing before starting is advisable given the compound's hepatic clearance and its effect on vitamin B6 metabolism.

Baseline labs should be drawn before the first dose, and ongoing labs repeated at roughly 3 months after starting and then every 6–12 months while use continues (sooner if any symptom arises).

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|----------------|
| ALT & AST | ~10–26 U/L | Screen liver stress from an unregulated compound cleared by the liver | ALT and AST are liver enzymes; conventional upper limits (~40 U/L) are looser than functional targets; fasting not required |
| Vitamin B6 (plasma pyridoxal 5'-phosphate) | ~30–80 nmol/L | Detect disruption from pyridoxal phosphatase inhibition | Fasting morning draw preferred; avoid high-dose B6 supplements for several days before testing |
| Complete blood count | Within standard reference limits | Baseline safety screen for an untested agent | CBC (complete blood count) surveys red cells, white cells, and platelets; pairs well with the metabolic panel |
| Fasting glucose & HbA1c | Glucose ~75–90 mg/dL; HbA1c <5.4% | Track the metabolic effects suggested in animal studies | HbA1c (glycated hemoglobin) reflects ~3-month average blood sugar; requires an overnight fast for glucose |
| Comprehensive metabolic panel | Within standard reference limits | Monitor kidney function and electrolytes over time | Includes kidney markers and electrolytes; fasting preferred; best paired with the liver enzymes above |

Qualitative markers to track alongside labs:

* **Cognitive clarity and memory:** subjective sharpness, word recall, and focus.
* **Mood and stress resilience:** day-to-day mood stability and response to stressors.
* **Energy levels:** daytime energy and motivation.
* **Sleep quality:** ease of falling asleep and restfulness, watching for any worsening tied to dose timing.

Success, in the absence of a validated endpoint, is best defined as a clear, sustained subjective benefit with no adverse change in the monitored biomarkers; the absence of benefit or any concerning lab shift is a reason to stop.

  
## Emerging Research

* **No registered human trials:** As of July 24, 2026, a search of ClinicalTrials.gov returned no registered interventional trials of 7,8-Dihydroxyflavone (or its prodrug R13) in humans, so there is no ongoing clinical trial with an NCT identifier to link; this remains the single largest gap in the evidence base.
* **Prodrug development (R13):** Medicinal-chemistry work continues on prodrugs such as R13, engineered for better oral absorption and durability with the aim of eventually enabling human trials in Alzheimer's disease and related conditions; progress is at the preclinical and patent stage.
* **Newly recognized enzyme target:** [7,8-Dihydroxyflavone is a direct inhibitor of human and murine pyridoxal phosphatase](https://pubmed.ncbi.nlm.nih.gov/38856179/) (Brenner et al., 2024) identifies a TrkB-independent mechanism that could reshape both benefit and risk interpretations and is a priority for follow-up — a study that could weaken the clean "selective TrkB agonist" narrative.
* **Metabolic and anti-inflammatory signals:** [7,8-Dihydroxyflavone Attenuates Inflammatory Response and Insulin Resistance Induced by the Paracrine Interaction between Adipocytes and Macrophages](https://pubmed.ncbi.nlm.nih.gov/36834930/) (Shin et al., 2023) exemplifies the expanding body-metabolism research that could strengthen the case for metabolic benefit if replicated and extended to humans.
* **Bone and musculoskeletal effects (both directions):** [The TrkB agonist, 7,8-dihydroxyflavone, impairs fracture healing in mice](https://pubmed.ncbi.nlm.nih.gov/34059571/) (Johnstone et al., 2021) is a cautionary signal, while [7,8-Dihydroxyflavone ameliorates bone loss by regulating TRKB/AKT/FOXO3a pathway in a mouse model of alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/41350438/) (Liu et al., 2025) points the opposite way, and reconciling these divergent bone findings is an important open question.
* **Future research areas that could change understanding:** first-in-human pharmacokinetic and safety studies; oncologic safety given TrkB's role in tumor survival; sex-specific metabolic and muscle effects; and head-to-head comparison of the parent compound against improved prodrugs. Both benefit-strengthening and benefit-weakening results are plausible, and the field will not resolve until controlled human data exist.

  
## Conclusion

7,8-Dihydroxyflavone is a plant-derived molecule that switches on the same brain receptor as a natural growth protein the body cannot easily deliver as a medicine. That elegant idea, plus more than a decade of animal work, explains its appeal to people focused on protecting thinking and brain health with age. In laboratory and animal studies it fairly consistently improves memory, protects neurons after injury, and lifts mood-related behavior, with more tentative signals for metabolism, movement disorders, eye health, and muscle. For someone oriented toward long-term health, the honest picture is of a compound rich in promise but thin in proof.

The central limitation dominates everything else: no completed human trials exist, so every benefit and every dose rests on extrapolation from rodents. Real concerns accompany the promise — impaired bone healing in mice, disruption of a vitamin B6 enzyme, a theoretical link to tumor growth, unstable and unregulated products, and simply unknown long-term effects in people. Much of the foundational research also comes from parties with patents or products to sell, which warrants a careful reading.

The evidence base is therefore best described as unusually deep in animals and nearly empty in humans, with the direction of translation still genuinely uncertain and actively debated on both sides.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**